Search research articles
Contact Us
Filters
Showing results (41-50 of 70) with videos related to
Page
of 7
Sort By:
Clinical Pharmacology and Therapeutics
|
April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study
Neeraj Gupta, Anna Largajolli, Han Witjes, et al.
Journal of Pediatric Orthopedics
|
May 1, 2026
Shielding of the Trunk During Extremity Imaging Reduces Radiation Exposure in Pediatric Patients
Simon Blanchard, Steven Zhang, William Huffman, et al.
Investigational New Drugs
|
May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants
Michael J Hanley, Steven Zhang, Robert Griffin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
March 6, 2025
Development of Hybrid radiomic Machine learning models for preoperative prediction of meningioma grade on multiparametric MRI
Steven Zhang, Jesse Richter, Jonathon Veale, et al.
Targeted Oncology
|
August 14, 2017
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Neeraj Gupta, Huyuan Yang, Michael J Hanley, et al.
Journal of Clinical Pharmacology
|
September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer
Steven Zhang, Peter Zannikos, Ahmad Awada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 22, 2024
Metabolism and Excretion of [<sup>14</sup>C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects
Hao Chen, Abhi Shah, Suguru Kato, et al.
Blood
|
February 4, 2021
Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice
Yue Sheng, Rui Ma, Chunjie Yu, et al.
Journal of Clinical Pharmacology
|
October 28, 2011
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects
Blisse Vakkalagadda, Jong-Soon Park, Christoph M Ahlers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2006
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function
Wandena S Siegel-Lakhai, Mirjam Crul, Peter De Porre, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 70) with videos related to
Sort By:
Page
of 7
Clinical Pharmacology and Therapeutics
|
April 25, 2022
Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with EGFR Exon 20 Insertions: Exposure-Response Analyses of a Pivotal Phase I/II Study
Neeraj Gupta, Anna Largajolli, Han Witjes, et al.
Journal of Pediatric Orthopedics
|
May 1, 2026
Shielding of the Trunk During Extremity Imaging Reduces Radiation Exposure in Pediatric Patients
Simon Blanchard, Steven Zhang, William Huffman, et al.
Investigational New Drugs
|
May 24, 2024
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [<sup>14</sup>C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants
Michael J Hanley, Steven Zhang, Robert Griffin, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
|
March 6, 2025
Development of Hybrid radiomic Machine learning models for preoperative prediction of meningioma grade on multiparametric MRI
Steven Zhang, Jesse Richter, Jonathon Veale, et al.
Targeted Oncology
|
August 14, 2017
Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses
Neeraj Gupta, Huyuan Yang, Michael J Hanley, et al.
Journal of Clinical Pharmacology
|
September 22, 2006
Pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer
Steven Zhang, Peter Zannikos, Ahmad Awada, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
July 22, 2024
Metabolism and Excretion of [<sup>14</sup>C]Mobocertinib, a Selective Covalent Inhibitor of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations, in Healthy Male Subjects
Hao Chen, Abhi Shah, Suguru Kato, et al.
Blood
|
February 4, 2021
Role of c-Myc haploinsufficiency in the maintenance of HSCs in mice
Yue Sheng, Rui Ma, Chunjie Yu, et al.
Journal of Clinical Pharmacology
|
October 28, 2011
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects
Blisse Vakkalagadda, Jong-Soon Park, Christoph M Ahlers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 30, 2006
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function
Wandena S Siegel-Lakhai, Mirjam Crul, Peter De Porre, et al.
Page
of 7